Published 18 minutes ago • loading... • Updated 26 minutes ago
Health Canada approves Eli Lilly's GLP-1 pill for weight loss
The once-daily pill is approved for adults with obesity or related conditions and is also cleared to help treat Type 2 diabetes.
On Nov. 13, Health Canada authorized Eli Lilly's Foundayo, a daily GLP-1 pill for weight loss, offering patients an alternative to weekly injections.
Patients may prefer oral medication over injections; because Foundayo is a smaller molecule than semaglutide and tirzepatide, it can be absorbed orally without digestive breakdown.
Foundayo is approved for adults with obesity or those who are overweight with related medical problems, and it also helps treat Type 2 diabetes.
Eli Lilly expects the pills to reach pharmacies in January, while Vancouver endocrinologist Dr. Ehud Ur said it "seems to be just as good as if not better" for weight loss.
Competitor Novo Nordisk currently markets Rybelsus for Type 2 diabetes in Canada, though its Wegovy pill still awaits Health Canada approval.